文献速递神经肿瘤

复发性胶质母细胞瘤患者是否应接受再次手术?单中心比较队列研究的结局分析

Should Redo Surgery be Offered to Patients with Relapsed Glioblastoma? - Outcome Analyses of a Single Institution Comparative Cohort Study.
PubMed 文献 · World Neurosurg · 2023-06-01

该回顾性单中心比较队列研究分析了2006至2015年间接受再次手术的复发性胶质母细胞瘤患者(G1组30例)与按年龄、初始治疗和无进展生存期匹配的对照组(G2组32例),发现G1组自首次诊断起的总生存期为109周(45-180),而G2组为57周(28-127),再次手术后并发症发生率为57%。作者认为再次手术对于体能状态良好、初始治疗后无进展生存期较长且有压迫症状的特定患者是可行的治疗选择,但需设计良好的随机对照试验来确定标准手术方案。

要点

  • G1组自首次诊断起总生存期109周(45-180),G2组为57周(28-127)。
  • 再次手术后并发症发生率为57%,包括出血、梗死、水肿致神经功能恶化、脑脊液漏和伤口感染。
  • G1组中50%接受再次手术的患者接受了二线化疗。

核心结论

  • 再次手术对于体能状态良好、初始治疗后无进展生存期较长且有压迫症状的特定复发性胶质母细胞瘤患者是可行的治疗选择。
  • 再次手术的使用因机构而异。
  • 需要设计良好的随机对照试验来确定该人群的标准手术治疗方案。

研究设计与样本

  • 回顾性单中心比较队列研究,纳入2006至2015年间在皇家斯托克大学医院(Royal Stoke University Hospitals)接受再次手术的复发性胶质母细胞瘤患者(G1组,30例),并按年龄、初始治疗和无进展生存期随机匹配对照组(G2组,32例)。

主要发现

  • G1组自首次诊断起总生存期为109周(45-180),G2组为57周(28-127)。
  • 再次手术后并发症发生率为57%,包括出血、梗死、水肿致神经功能恶化、脑脊液漏和伤口感染。
  • G1组中50%接受再次手术的患者接受了二线化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma multiforme (GBM) is the predominant malignant brain tumor originating intracranially. The established first-line treatment postsurgery is concurrent chemoradiation as a definitive measure. However, recurrent GBM's pose a challenge for clinicians who rely on institutional experience to determine the most suitable course of action. Second-line chemotherapy may be administered with or without surgery depending on the institution's practice. This study aims to present our tertiary center institution's experience with recurrent GBM patients who underwent redo surgery. METHODS: In this retrospective study we analyzed the surgical and oncological data of patients with recurrent GBM who underwent redo surgery at the Royal Stoke University Hospitals between 2006 and 2015. The group 1 (G1) comprised the reviewed patients, while a control group (G2) was randomly selected, matching the reviewed group by age, primary treatment, and progression-free survival (PFS). The study collected data on various parameters, including overall survival, PFS, extent of surgical resection, and postoperative complications. RESULTS: This retrospective study included 30 patients in G1 and 32 patients in G2, matched based on age, primary treatment, and PFS. The study found that the overall survival for the G1 group from the time of first diagnosis was 109 weeks (45-180) compared to 57 weeks (28-127) in the G2 group. The incidence of postoperative complications after the second surgery was 57%, which included hemorrhage, infarction, worsening neurology due to edema, cerebrospinal fluid leak, and wound infection. Furthermore, 50% of the patients in the G1 group who underwent redo surgery received second-line chemotherapy. CONCLUSIONS: Our study found that redo surgery for recurrent GBM is a viable treatment option for a select group of patients with good performance status, longer PFS from primary treatment, and compressive symptoms. However, the use of redo surgery varies depending on the institution. A well-designed randomized controlled trial in this population would help establish the standard of surgical care.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Eltoukhy M, Kandula V, Joseph S, et al. Should Redo Surgery be Offered to Patients with Relapsed Glioblastoma? - Outcome Analyses of a Single Institution Comparative Cohort Study. World Neurosurg. 2023. PMID: 37268188. doi:10.1016/j.wneu.2023.05.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。